Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Abilify; Belgium: Abilify; Bulgaria: Abilify; Cyprus: Abilify; Czech Republic: Abilify; Denmark: Abilify; Estonia: Abilify; Finland: Abilify; France: Abilify; Germany: Abilify; Greece: Abilify; Hungary: Abilify; Ireland: Abilify; Italy: Abilify; Latvia: Abilify; Lithuania: Abilify; Luxembourg: Abilify; Malta: Abilify; Netherlands: Abilify; Poland: Abilify; Portugal: Abilify; Romania: Abilify; Slovakia: Abilify; Slovenia: Abilify; Spain: Abilify; Sweden: Abilify; UK: Abilify.

North America

Canada: Abilify; USA: Abilify.

Latin America

Argentina: Arixind, Arlemide, Groven, Irazem, Lemidal, Siblix; Brazil: Abilify; Mexico: Abilify.


Japan: Abilify.

Drug combinations


Aripiprazole: C~23~H~27~Cl~2~N~3~O~2~. Mw: 448.39. (1) 2(1H)-Quinolinone, 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-; (2) 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril. CAS-129722-12-9 (1997).

Pharmacologic Category

Antimanic Agents. Atypical Antipsychotics. (ATC-Code: N05AX12).

Mechanism of action

Partial agonist at the D~2~ and 5-HT~1A~ receptors, and as an antagonist at the 5-HT~2A~ receptor.

Therapeutic use

Symptomatic management of schizophrenia. Management of acute psychotic episodes. Treatment of acute manic and mixed episodes associated with bipolar disorder. Agitation associated with schizophrenia or bipolar mania. Major depressive disorder.

Pregnancy and lactiation implications

Developmental toxicity and teratogenic effects in animal models. Should be used in pregnancy only when potential benefit to mother outweighs possible risk to the fetus. Not recommended for use during lactation.

Unlabeled use

Depression with psychotic features. Aggression (children). Conduct disorder (children). Tourette’s syndrome (children). Psychosis/agitation related to Alzheimer’s dementia.


Hypersensitivity to aripiprazole or any component of the formulation.

Warnings and precautions

Risk of suicide attempt in major depressive disorder and other psychiatric disorders. Not FDA-approved for adjunctive treatment of depression in children. Increased risk of mortality in elderly patients treated for dementia-related psychosis. May alter cardiac conduction. May cause esophageal dysmotility and aspiration, extrapyramidal symptoms (pseudoparkinsonism, acute dystonic reactions, akathisia, tardive dyskinesia), hyperglycemia, neuroleptic malignant syndrome, orthostatic hypotension, sedation, impaired temperature regulation, and weight gain. Use with caution in cardiac disease, cerebrovascular disease, or conditions which predispose to hypotension, in Parkinson’s disease, or in patients at risk of seizures. Some products contain phenylalanine.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart